Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.

Yizhang Liu Kun Hu Lu Jian Yongfang Duan Mi Zhang Yehong Kuang

Published in: The Journal of dermatological treatment (2024)

Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.

Keyphrases

rheumatoid arthritis
newly diagnosed
end stage renal disease
randomized controlled trial
systematic review
ulcerative colitis
prognostic factors
hidradenitis suppurativa
emergency department